AVITA Medical (RCEL) Stock Forecast, Price Target & Predictions


OverviewOwnershipChartTranscripts

RCEL Stock Forecast


AVITA Medical stock forecast is as follows: an average price target of $9.00 (represents a -30.07% downside from RCEL’s last price of $12.87) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

RCEL Price Target


The average price target for AVITA Medical (RCEL) is $9.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $9.00 to $9.00. This represents a potential -30.07% downside from RCEL's last price of $12.87.

RCEL Analyst Ratings


Buy

According to 5 Wall Street analysts, AVITA Medical's rating consensus is 'Buy'. The analyst rating breakdown for RCEL stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

AVITA Medical Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 14, 2024Matt O'BrienPiper Sandler$9.00$8.357.78%-30.07%
Row per page
Go to

The latest AVITA Medical stock forecast, released on May 14, 2024 by Matt O'Brien from Piper Sandler, set a price target of $9.00, which represents a 7.78% increase from the stock price at the time of the forecast ($8.35), and a -30.07% decrease from RCEL last price ($12.87).

AVITA Medical Price Target by Period


1M3M12M
# Anlaysts--1
Avg Price Target--$9.00
Last Closing Price$12.87$12.87$12.87
Upside/Downside-100.00%-100.00%-30.07%

In the current month, the average price target of AVITA Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to AVITA Medical's last price of $12.87. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Aug 09, 2024Cowen & Co.BuyBuyHold
May 14, 2024Bank of America SecuritiesBuyBuyHold
May 14, 2024Piper Sandler-NeutralDowngrade
Jun 27, 2023Cantor Fitzgerald-OverweightInitialise
Jun 16, 2021BTIGBuyBuyHold
Row per page
Go to

AVITA Medical's last stock rating was published by Cowen & Co. on Aug 09, 2024. The company gave RCEL a "Buy" rating, the same as its previous rate.

AVITA Medical Financial Forecast


AVITA Medical Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
Revenue-------------$13.64M$11.75M$10.55M$9.46M$9.09M$8.34M$7.54M$6.94M$7.02M$10.30M$8.77M$5.10M$5.06M$3.88M
Avg Forecast$17.26M$17.54M$17.82M$18.10M$33.07M$29.43M$25.67M$22.03M$23.20M$19.44M$14.52M$11.08M$14.20M$13.40M$11.30M$10.28M$8.80M$7.48M$7.32M$7.24M$8.28M$7.33M$4.94M$5.10M$3.88M$7.97M$3.61M
High Forecast$17.86M$18.15M$18.44M$18.73M$34.22M$30.46M$26.56M$22.80M$24.01M$20.12M$15.02M$11.47M$15.89M$13.87M$11.69M$10.64M$9.11M$7.48M$7.32M$7.24M$8.28M$7.33M$4.94M$5.10M$3.88M$7.97M$3.61M
Low Forecast$16.60M$16.87M$17.14M$17.41M$31.81M$28.31M$24.69M$21.19M$22.32M$18.70M$13.96M$10.66M$13.36M$12.89M$10.87M$9.89M$8.46M$7.48M$7.32M$7.24M$8.28M$7.33M$4.94M$5.10M$3.88M$7.97M$3.61M
# Analysts111111123144544433334444444
Surprise %-------------1.02%1.04%1.03%1.07%1.21%1.14%1.04%0.84%0.96%2.09%1.72%1.32%0.64%1.07%

AVITA Medical's average Quarter revenue forecast for Dec 23 based on 5 analysts is $14.20M, with a low forecast of $13.36M, and a high forecast of $15.89M. RCEL's average Quarter revenue forecast represents a 4.03% increase compared to the company's last Quarter revenue of $13.64M (Sep 23).

AVITA Medical EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts111111123144544433334444444
EBITDA-------------$-8.53M$8.31M$-9.05M$-5.19M$-5.44M$-6.12M$-9.46M$-8.45M$-5.76M$-4.53M$-5.82M$-5.46M$-10.00M$-12.90M
Avg Forecast$-16.51M$-16.77M$-17.04M$-17.32M$-31.63M$-28.15M$-24.55M$-21.08M$-22.19M$-18.59M$-13.89M$-11.82M$-13.58M$-12.82M$-10.81M$-12.22M$-12.28M$-7.16M$-7.00M$-11.69M$-7.92M$-7.01M$-4.72M$-8.66M$-3.71M$-7.62M$-10.24M
High Forecast$-15.88M$-16.13M$-16.39M$-16.66M$-30.42M$-27.08M$-23.61M$-20.27M$-21.35M$-17.89M$-13.36M$-9.46M$-12.78M$-12.33M$-10.40M$-9.78M$-9.82M$-7.16M$-7.00M$-9.35M$-7.92M$-7.01M$-4.72M$-6.92M$-3.71M$-7.62M$-8.19M
Low Forecast$-17.08M$-17.36M$-17.64M$-17.92M$-32.73M$-29.13M$-25.40M$-21.81M$-22.96M$-19.24M$-14.37M$-14.18M$-15.20M$-13.26M$-11.18M$-14.66M$-14.73M$-7.16M$-7.00M$-14.03M$-7.92M$-7.01M$-4.72M$-10.39M$-3.71M$-7.62M$-12.29M
Surprise %-------------0.67%-0.77%0.74%0.42%0.76%0.87%0.81%1.07%0.82%0.96%0.67%1.47%1.31%1.26%

4 analysts predict RCEL's average Quarter EBITDA for Sep 23 to be $-12.82M, with a high of $-12.33M and a low of $-13.26M. This is -254.22% lower than AVITA Medical's previous annual EBITDA (Jun 23) of $8.31M.

AVITA Medical Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts111111123144544433334444444
Net Income-------------$-8.71M$-10.38M$-9.22M$-5.35M$-5.59M$-6.26M$-9.46M$-8.48M$-5.95M$-4.72M$-6.00M$-5.64M$-10.23M$-12.91M
Avg Forecast$-3.78M$-3.78M$-7.55M$-7.55M$-3.21M$-6.04M$-10.95M$-15.96M$-13.54M$-15.94M$-18.32M$-12.03M$-14.12M$-17.27M$-11.97M$-12.44M$-12.67M$-13.00M$-12.67M$-11.90M$-10.23M$-12.28M$-16.52M$-8.92M$-5.41M$-4.74M$-10.25M
High Forecast$-3.59M$-3.59M$-7.18M$-7.18M$-3.05M$-5.74M$-10.41M$-15.17M$-12.87M$-15.15M$-17.41M$-9.63M$-13.42M$-16.42M$-11.38M$-9.95M$-10.14M$-13.00M$-12.67M$-9.52M$-10.23M$-12.28M$-16.52M$-7.14M$-5.41M$-4.74M$-8.20M
Low Forecast$-3.95M$-3.95M$-7.90M$-7.90M$-3.36M$-6.32M$-11.45M$-16.68M$-14.16M$-16.67M$-19.14M$-14.44M$-14.76M$-18.05M$-12.52M$-14.93M$-15.21M$-13.00M$-12.67M$-14.28M$-10.23M$-12.28M$-16.52M$-10.71M$-5.41M$-4.74M$-12.30M
Surprise %-------------0.50%0.87%0.74%0.42%0.43%0.49%0.80%0.83%0.48%0.29%0.67%1.04%2.16%1.26%

AVITA Medical's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RCEL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

AVITA Medical SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts111111123144544433334444444
SG&A-------------$16.66M$-3.84M$14.84M$11.66M$10.41M$10.80M$12.36M$10.60M$8.87M$9.42M$9.07M$7.00M$11.74M$14.67M
Avg Forecast$127.28M$129.32M$131.39M$133.50M$243.85M$217.06M$189.28M$162.49M$171.09M$143.36M$107.05M$81.71M$104.68M$98.82M$83.33M$75.81M$64.90M$55.19M$53.96M$53.39M$61.02M$54.02M$36.41M$37.61M$28.61M$58.76M$26.63M
High Forecast$131.70M$133.82M$135.97M$138.15M$252.34M$224.61M$195.87M$168.14M$177.04M$148.35M$110.78M$84.55M$117.19M$102.26M$86.23M$78.45M$67.15M$55.19M$53.96M$53.39M$61.02M$54.02M$36.41M$37.61M$28.61M$58.76M$26.63M
Low Forecast$122.42M$124.39M$126.38M$128.41M$234.56M$208.79M$182.07M$156.29M$164.57M$137.90M$102.97M$78.60M$98.50M$95.05M$80.16M$72.92M$62.42M$55.19M$53.96M$53.39M$61.02M$54.02M$36.41M$37.61M$28.61M$58.76M$26.63M
Surprise %-------------0.17%-0.05%0.20%0.18%0.19%0.20%0.23%0.17%0.16%0.26%0.24%0.24%0.20%0.55%

AVITA Medical's average Quarter SG&A projection for Dec 23 is $104.68M, based on 5 Wall Street analysts, with a range of $98.50M to $117.19M. The forecast indicates a 528.50% rise compared to RCEL last annual SG&A of $16.66M (Sep 23).

AVITA Medical EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts111111123144544433334444444
EPS-------------$-0.34$-0.41$-0.37$-0.24$-0.22$-0.25$-0.38$-0.34$-0.24$-0.19$-0.26$-0.26$-0.48$-0.61
Avg Forecast$-0.15$-0.15$-0.30$-0.30$-0.13$-0.24$-0.43$-0.63$-0.53$-0.63$-0.72$-0.53$-0.56$-0.68$-0.47$-0.40$-0.35$-0.51$-0.50$-0.46$-0.40$-0.48$-0.65$-0.35$-0.21$-0.19$-0.20
High Forecast$-0.14$-0.14$-0.28$-0.28$-0.12$-0.23$-0.41$-0.60$-0.51$-0.60$-0.69$-0.50$-0.53$-0.65$-0.45$-0.38$-0.34$-0.51$-0.50$-0.46$-0.40$-0.48$-0.65$-0.35$-0.21$-0.19$-0.20
Low Forecast$-0.16$-0.16$-0.31$-0.31$-0.13$-0.25$-0.45$-0.66$-0.56$-0.66$-0.75$-0.55$-0.58$-0.71$-0.49$-0.42$-0.37$-0.51$-0.50$-0.46$-0.40$-0.48$-0.65$-0.35$-0.21$-0.19$-0.20
Surprise %-------------0.50%0.87%0.92%0.68%0.43%0.50%0.82%0.84%0.50%0.29%0.74%1.22%2.57%3.07%

According to undefined Wall Street analysts, AVITA Medical's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RCEL previous annual EPS of $NaN (undefined).

AVITA Medical Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
APYXApyx Medical$1.34$8.50534.33%Buy
TELATELA Bio$3.06$12.50308.50%Buy
DCTHDelcath Systems$9.41$22.00133.79%Buy
SGHTSight Sciences$3.98$9.00126.13%Hold
LUNGPulmonx$6.72$11.9377.53%Buy
RXSTRxSight$44.65$70.1157.02%Buy
SIBNSI-BONE$13.14$20.0052.21%Buy
NPCENeuroPace$9.15$12.8840.77%Buy
TMDXTransMedics Group$92.73$126.7536.69%Buy
OFIXOrthofix Medical$18.64$24.0028.76%-
VREXVarex Imaging$13.92$17.0022.13%Buy
CVRXCVRx$14.20$16.3315.00%Buy
CLPTClearPoint Neuro$10.95$12.009.59%Buy
IRMDIRadimed$55.45$60.008.21%Buy
RCELAVITA Medical$12.87$9.00-30.07%Buy

RCEL Forecast FAQ


Is AVITA Medical a good buy?

Yes, according to 5 Wall Street analysts, AVITA Medical (RCEL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of RCEL's total ratings.

What is RCEL's price target?

AVITA Medical (RCEL) average price target is $9 with a range of $9 to $9, implying a -30.07% from its last price of $12.87. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will AVITA Medical stock go up soon?

According to Wall Street analysts' prediction for RCEL stock, the company can go down by -30.07% (from the last price of $12.87 to the average price target of $9), down by -30.07% based on the highest stock price target, and down by -30.07% based on the lowest stock price target.

Can AVITA Medical stock reach $20?

RCEL's average twelve months analyst stock price target of $9 does not support the claim that AVITA Medical can reach $20 in the near future.

What are AVITA Medical's analysts' financial forecasts?

AVITA Medical's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $110.2M (high $114.04M, low $106M), average EBITDA is $-105M (high $-101M, low $-109M), average net income is $-36.169M (high $-34.376M, low $-37.805M), average SG&A $812.68M (high $840.96M, low $781.7M), and average EPS is $-1.424 (high $-1.353, low $-1.488). RCEL's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $70.71M (high $73.17M, low $68.02M), average EBITDA is $-67.639M (high $-65.061M, low $-69.993M), average net income is $-22.664M (high $-21.541M, low $-23.69M), average SG&A $521.49M (high $539.63M, low $501.61M), and average EPS is $-0.892 (high $-0.848, low $-0.933).

Did the RCEL's actual financial results beat the analysts' financial forecasts?

Based on AVITA Medical's last annual report (Dec 2022), the company's revenue was $34.42M, beating the average analysts forecast of $30.84M by 11.61%. Apple's EBITDA was $-26.045M, missing the average prediction of $-38.127M by -31.69%. The company's net income was $-26.665M, missing the average estimation of $-50.25M by -46.94%. Apple's SG&A was $45.24M, missing the average forecast of $227.43M by -80.11%. Lastly, the company's EPS was $-1.07, missing the average prediction of $-1.829 by -41.50%. In terms of the last quarterly report (Sep 2023), AVITA Medical's revenue was $13.64M, beating the average analysts' forecast of $13.4M by 1.83%. The company's EBITDA was $-8.527M, missing the average prediction of $-12.817M by -33.47%. AVITA Medical's net income was $-8.712M, missing the average estimation of $-17.271M by -49.56%. The company's SG&A was $16.66M, missing the average forecast of $98.82M by -83.15%. Lastly, the company's EPS was $-0.34, missing the average prediction of $-0.68 by -49.99%